Myeloproliferative Disorders clinical trials at UC Cancer
1 research study open to eligible people
open to eligible people ages 18 years and up
Phase 1 Part (Complete): Open-label, sequential dose escalation study of CPI-0610 in patients with previously treated Acute Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasms, and Myelofibrosis. Phase 2 Part: Open-label study of CPI-0610 with and without Ruxolitinib in patients with Myelofibrosis. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.
Our lead scientists for Myeloproliferative Disorders medical studies include Gary Schiller, MD.